(Reuters) - Verily, Alphabet Inc's
The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears.
Verily on Friday cited https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.
Verily, which was previously part of the tech giant's Google X research and development unit, had partnered with Novartis'
Novartis did not immediately respond to a request for comment.
Verily said it would continue to work with Alcon on two other programs, a smart accommodating contact lens for presbyopia, or far-sightedness, and a smart intraocular lens for improving sight following cataract surgery.
Verily received an $800 million investment from Singapore state investor Temasek last year.
(Reporting by Munsif Vengattil in Bengaluru and Paresh Dave in San Francisco; Editing by Maju Samuel)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Firstpost is now on WhatsApp. For the latest analysis, commentary and news updates, sign up for our WhatsApp services. Just go to Firstpost.com/Whatsapp and hit the Subscribe button.
Updated Date: Nov 17, 2018 01:05:53 IST